Bladder Cancer - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 742
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B363EFB63CFEN
Leaflet:

Download PDF Leaflet

Bladder Cancer - Pipeline Review, H2 2016
Bladder Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer – Pipeline Review, H2 2016, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.Bladder Cancer.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Bladder Cancer Overview
Therapeutics Development
Bladder Cancer - Therapeutics under Development by Companies
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes
Bladder Cancer - Pipeline Products Glance
Bladder Cancer - Products under Development by Companies
Bladder Cancer - Products under Investigation by Universities/Institutes
Bladder Cancer - Companies Involved in Therapeutics Development
Bladder Cancer - Therapeutics Assessment
Drug Profiles
Bladder Cancer - Dormant Projects
Bladder Cancer - Discontinued Products
Bladder Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Bladder Cancer, H2 2016
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Investigation by Universities/Institutes, H2 2016
Bladder Cancer - Pipeline by 4SC AG, H2 2016
Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2016
Bladder Cancer - Pipeline by Agenus Inc, H2 2016
Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2016
Bladder Cancer - Pipeline by AndroScience Corporation, H2 2016
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2016
Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2016
Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Bladder Cancer - Pipeline by Aura Biosciences, Inc., H2 2016
Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
Bladder Cancer - Pipeline by Bayer AG, H2 2016
Bladder Cancer - Pipeline by BioCancell Ltd, H2 2016
Bladder Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
Bladder Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016
Bladder Cancer - Pipeline by Biotest AG, H2 2016
Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Bladder Cancer - Pipeline by Celgene Corporation, H2 2016
Bladder Cancer - Pipeline by Cellceutix Corporation, H2 2016
Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Celprogen, Inc., H2 2016
Bladder Cancer - Pipeline by Celsion Corporation, H2 2016
Bladder Cancer - Pipeline by Codagenix, Inc., H2 2016
Bladder Cancer - Pipeline by Cold Genesys, Inc., H2 2016
Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
Bladder Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2016
Bladder Cancer - Pipeline by Eisai Co., Ltd., H2 2016
Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc., H2 2016
Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2016
Bladder Cancer - Pipeline by Elsalys Biotech SAS, H2 2016
Bladder Cancer - Pipeline by enGene, Inc, H2 2016
ancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Bladder Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2016
Bladder Cancer - Pipeline by Genmab A/S, H2 2016
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Bladder Cancer - Pipeline by H3 Biomedicine Inc., H2 2016
Bladder Cancer - Pipeline by Hamlet Pharma AB, H2 2016
Bladder Cancer - Pipeline by Heat Biologics, Inc., H2 2016
Bladder Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2016
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by ImmuNext, Inc., H2 2016
Bladder Cancer - Pipeline by Immunocore Limited, H2 2016
Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2016
Bladder Cancer - Pipeline by Immupharma Plc, H2 2016
Bladder Cancer - Pipeline by InteRNA Technologies B.V., H2 2016
Bladder Cancer - Pipeline by Johnson & Johnson, H2 2016
Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H2 2016
Bladder Cancer - Pipeline by MacroGenics, Inc., H2 2016
Bladder Cancer - Pipeline by MaxiVAX SA, H2 2016
Bladder Cancer - Pipeline by Meabco A/S, H2 2016
Bladder Cancer - Pipeline by Medicenna Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by MedImmune LLC, H2 2016
Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2016
Bladder Cancer - Pipeline by Merck KGaA, H2 2016
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2016
Bladder Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016
Bladder Cancer - Pipeline by Moleculin Biotech Inc, H2 2016
Bladder Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
Bladder Cancer - Pipeline by Nektar Therapeutics, H2 2016
Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2016
Bladder Cancer - Pipeline by Omeros Corporation, H2 2016
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
Bladder Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016
Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2016
Bladder Cancer - Pipeline by Pfizer Inc., H2 2016
Bladder Cancer - Pipeline by Pharma Mar, S.A., H2 2016
Bladder Cancer - Pipeline by Philogen S.p.A., H2 2016
Bladder Cancer - Pipeline by Plexxikon Inc., H2 2016
Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016
Bladder Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by Rodos BioTarget GmbH, H2 2016
Bladder Cancer - Pipeline by Sanofi, H2 2016
Bladder Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by Serometrix, LLC, H2 2016
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016
Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016
Bladder Cancer - Pipeline by Synovo GmbH, H2 2016
Bladder Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Bladder Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
Bladder Cancer - Pipeline by Taris Biomedical LLC, H2 2016
Bladder Cancer - Pipeline by Telormedix SA, H2 2016
Bladder Cancer - Pipeline by TesoRx Pharma LLC, H2 2016
Bladder Cancer - Pipeline by Theravectys SA, H2 2016
Bladder Cancer - Pipeline by Theryte Limited, H2 2016
Bladder Cancer - Pipeline by Transgene SA, H2 2016
Bladder Cancer - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2016
Bladder Cancer - Pipeline by Vault Pharma Inc., H2 2016
Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2016
Bladder Cancer - Pipeline by Vaxiion Therapeutics, Inc., H2 2016
Bladder Cancer - Pipeline by Viralytics Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bladder Cancer - Dormant Projects, H2 2016
Bladder Cancer - Dormant Projects (Contd..1), H2 2016
Bladder Cancer - Dormant Projects (Contd..2), H2 2016
Bladder Cancer - Dormant Projects (Contd..3), H2 2016
Bladder Cancer - Dormant Projects (Contd..4), H2 2016
Bladder Cancer - Dormant Projects (Contd..5), H2 2016
Bladder Cancer - Dormant Projects (Contd..6), H2 2016
Bladder Cancer - Dormant Projects (Contd..7), H2 2016
Bladder Cancer - Dormant Projects (Contd..8), H2 2016
Bladder Cancer - Dormant Projects (Contd..9), H2 2016
Bladder Cancer - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Bladder Cancer, H2 2016
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Head And Neck Cancer - Pipeline Review, H2 2016 US$ 2,500.00 Oct, 2016 · 1153 pages
Gastric Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 963 pages

Ask Your Question

Bladder Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: